TOLERRX, INC

Oct 21, 09
	NEW STORY
11:45 ET	Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Aug 11, 09
08:05 ET	Tolerx Announces Amendment to Phase 3 DEFEND Protocol
Jun 08, 09
10:45 ET	Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Mar 10, 09
08:00 ET	Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Aug 06, 08
08:00 ET	Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Aug 05, 08
08:00 ET	Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
Jun 24, 08
11:00 ET	Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008
Jun 03, 08
08:00 ET	Tolerx Announces Data Presentations at American Diabetes Association 68th Scientific Sessions 2008
Apr 09, 08
08:00 ET	Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
Jan 15, 08
08:00 ET	Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Aug 16, 06
09:42 ET	TolerRx, Inc. Raises $35.6 Million to Advance TRX4 in Type 1 Diabetes
Feb 14, 06
08:08 ET	TolerRx Receives Orphan Drug Designation from FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
Dec 07, 05
08:03 ET	TolerRx Initiates Three Clinical Trials in Autoimmune Indications
Nov 29, 05
08:03 ET	TolerRx, Inc. Announces Manufacturing and Commercial Supply Agreement with Abbott for TRX4
Jun 23, 05
17:00 ET	Positive Data from Type 1 Diabetes Study of TolerRx's TRX4 Published in the New England Journal of Medicine
Apr 04, 05
08:32 ET	TolerRx, Inc. Acquires Assets for Lead Product, TRX4
Mar 29, 05
08:32 ET	TolerRx, Inc. Completes $31 Million Series D Financing
Aug 02, 04
08:04 ET	TolerRx Initiates Clinical Trial of TRX4 for Psoriasis
Jul 26, 04
08:33 ET	TolerRx Withdraws Registration Statement